in natural products with cytotoxic activity4a and show
promise as hGPR91 antagonists,4b glutamate carboxypep-
tidase II (GCPII) inhibitors,4c Bradykinin B1 receptor
(B1R) antagonists,4d,e and 3-HAO inhibitors,4f a general
method allowing their direct synthesis via ortho-arylation
of ortho-substituted benzoic acids would be highly useful.
development of such a method, resulting in an efficient and
practical protocol for the synthesis of these highly hindered
benzoic acids.
Table 1. Selected Optimization Resultsa
Scheme 1. Synthetic Approach to 2-Aryl-6-Substituted Benzoic
Acids 3
Pd
Ag2CO3
equiv
temp
yield (%)b
entry
mol %
additive
(°C)
3a þ 4a
1c
2
2
2
2
4
1
2
2
2
2
2
2
2
2
1
ꢀ
130
120
120
120
120
120
120
120
120
120
120
130
120
22 þ 75
70 þ 11
7 þ 80
1
ꢀ
3d
4
1
ꢀ
1
ꢀ
10 þ 70
42 þ 6
5
1
ꢀ
6
0.5
0.5
0.5
0.5
0.5
0.55
0.55
0.55
ꢀ
22 þ 70
56 þ 5
7
Li2CO3
Na2CO3
K2CO3
Cs2CO3
K2CO3
K2CO3
K2CO3
8
47 þ 10.5
70 þ 4.5
73 þ 5
9
10
11
12
13d
81 (76)e þ 5
78 þ 5
81 þ 5.5
a Unless otherwise noted, all reactions were carried out using Pd-
(OAc)2 as the catalyst, Ag2CO3, 1 equiv of 1a, and 3 equiv of 2a in AcOH
as a solventfor 24 h. b Yields were determined by 1H NMR analysis using
1,3,5-trimethoxybenzene as an internal standard. c Reaction run for 16 h.
d Reaction run for 67 h. e Yield of the isolated pure product 3a is shown in
parentheses.
Previous studies in our group have shown that the core
to the difficulty in synthesizing 2-aryl-6-substituted ben-
zoic acids is their intrinsic instability toward Pd-catalyzed
protodecarboxylation under the reaction conditions
(Scheme 1, path A).5 In line with our experimental observa-
tion, recent DFT studies on decarboxylation reactions
have concluded that ortho substituents can significantly
enhance metal-catalyzed protodecarboxylation.6 To access
the elusive 2-aryl-6-substituted benzoic acids it would be
necessary to develop a catalytic system where the Pd-
mediated decarboxylation event could be switched off after
the coupling has occurred (path B). Herein, we disclose the
On the basis of our previous work5 and Daugulis’
pioneering studies,3b the reaction optimization was carried
out with ortho-substituted benzoic acid 1a and iodoarene
2a as the coupling partner in a Pd/Ag system (Table 1).
Implementation of our previously reported conditions, as
expected, led to decarboxylated biaryl 4a as the major
product (entry 1). Lowering the reaction temperature to
120 °C minimized the protodecarboxylation step and
allowed the formation of the desired product, 3a (entry 2).7
However, under these conditions benzoic acid3a proved to
be very sensitive toward protodecarboxylation with longer
reaction times favoring this undesired process (entry 3).
Seeking a more robust catalytic system, we confirmed that
Pd species (and not Ag) were responsible for the decarbox-
ylation of the product 3a: raising the catalyst loading to
4 mol % appeared to promote extrusion of CO2, allowing
good conversion to side product 4a (entry 4). On the
contrary, low catalyst loadings led to a slower decarbox-
ylation although these conditions proved to be counter-
productive as they compromise the ortho-arylation
step (entry 5). On the other hand, decreasing the amount
of Ag2CO3 to 0.5 equiv led to a significant increase in
€
(4) (a) Aly, A. H.; Edrada-Ebel, R.; Indriani, I. D.; Wray, V.; Muller,
W. E. G.; Totzke, F.; Zirrgiebel, U.; Schachtele, C.; Kubbutat, M. H. G.;
€
Lin, W. H.; Proksch, P.; Ebel, R. J. Nat. Prod. 2008, 71, 972. (b)
Bhuniya, D.; Umrani, D.; Dave, B.; Salunke, D.; Kukreja, G.; Gundu,
J.; Naykodi, M.; Shaikh, N. S.; Shitole, P.; Kurhade, S.; De, S.;
Majumdar, S.; Reddy, S. B.; Tambe, S.; Shejul, Y.; Chugh, A.; Palle,
V. P.; Mookhtiar, K. a; Cully, D.; Vacca, J.; Chakravarty, P. K.;
Nargund, R. P.; Wright, S. D.; Graziano, M. P.; Singh, S. B.; Roy, S.;
Cai, T.-Q. Bioorg. Med. Chem. Lett. 2011, 21, 3596. (c) Stoermer, D.;
Vitharana, D.; Hin, N.; Delahanty, G.; Duvall, B.; Ferraris, D. V;
Grella, B. S.; Hoover, R.; Rojas, C.; Shanholtz, M. K.; Smith, K. P.;
Stathis, M.; Wu, Y.; Wozniak, K. M.; Slusher, B. S.; Tsukamoto, T. J.
Med. Chem. 2012, 55, 5922. (d) Huang, H.; Placer, M. P. J. Med. Chem.
2010, 53, 5383. (e) Kuduk, S. D.; Di Marco, C. N.; Chang, R. K.; Wood,
M. R.; Schirripa, K. M.; Kim, J. J.; Wai, J. M. C.; DiPardo, R. M.;
Murphy, K. L.; Ransom, R. W.; Harrell, C. M.; Reiss, D. R.; Holahan,
M. A.; Cook, J.; Hess, J. F.; Sain, N.; Urban, M. O.; Tang, C. J. Med.
€
Chem. 2007, 50, 272. (f) Linderberg, M.; Hellberg, S.; Bjork, S.;
€
Gotthammar, B.; Hogberg, T. Eur. J. Med. Chem. 1999, 34, 729.
(5) Cornella, J.; Righi, M.; Larrosa, I. Angew. Chem., Int. Ed. 2011,
50, 9429.
(6) (a) Xue, L.; Su, W.; Lin, Z. Dalton Trans. 2011, 40, 11926. (b) Xue,
L.; Su, W.; Lin, Z. Dalton Trans. 2010, 39, 9815.
(7) For the initial screening of solvents and various palladium and
silver sources, see Table S1 in the Supporting Information.
Org. Lett., Vol. 15, No. 4, 2013
911